This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vallette-Kasic, S. Articles by Brue, T. Search for Related Content PubMed PubMed Citation Articles by Vallette-Kasic, S. Articles by Brue, T.

Combined Pituitary Hormone Deficiency due to the F135C Human Pit-1 (Pituitary-Specific Factor 1) Gene Mutation: Functional and Structural Correlates

Laboratory ICNE UMR 6544 (S.V.-K., I.P.-B., G.G., A.D., A.E., T.B.) Ingéniérie des Protéines, UMR 6560 (F.S.) IFR Jean-Roche Faculté de Médecine Nord 13916 Marseille Cedex 20, France
Division of Endocrinology Children’s Hospital (S.R.) Harvard Medical School Boston, Massachusetts 02115

The pituitary-specific transcription factor Pit-1 (pituitary-specific factor 1) is known to play a key role in the differentiation of PRL-, GH-, and TSH-secreting cells, and in the regulation of expression of the corresponding genes. In recent years, 12 distinct mutations of the Pit-1 gene have been shown to be responsible for a phenotype of multiple congenital pituitary hormone deficiency involving PRL, GH, and TSH. We had previously identified, in four siblings with GH, PRL, and TSH deficiencies, a mutation (F135C) resulting in a single amino acid change within the POU-specific binding domain of the Pit-1 molecule. In the present report, we have explored the functional effect of the F135C mutation. In vitro activity tests performed by transfection in human HeLa cells showed decreased transactivation capacity on the PRL, GH, and Pit-1 genes. The DNA binding experiments performed by gel shift showed that the F135C mutation generated a protein capable of binding to DNA response elements. To analyze how the F135C mutation might affect functionality of the transcription factor despite a normal DNA binding, we used a structure modelization approach and also analyzed two other Pit-1 mutant proteins (F135A and F135Y). The loss of functionality in these two mutants was similar to that of F135C. This finding was in keeping with our molecular modeling studies. According to structural data derived from the crystallographic analysis of the DNA/Pit-1 POU domain complex, the conformation of the first helix of the F135C-mutated POU-specific domain could be perturbed to such an extent that any interaction with other transcription cofactors might be definitively prevented.

This article has been cited by other articles:

				I. Pellegrini, C. Roche, M.-H. Quentien, M. Ferrand, G. Gunz, S. Thirion, C. Bagnis, A. Enjalbert, and J.-L. Franc Involvement of the Pituitary-Specific Transcription Factor Pit-1 in Somatolactotrope Cell Growth and Death: An Approach Using Dominant-Negative Pit-1 Mutants Mol. Endocrinol., December 1, 2006; 20(12): 3212 - 3227. [Abstract] [Full Text] [PDF]

				I. Miyata, S. Vallette-Kasic, A. Saveanu, M. Takeuchi, H. Yoshikawa, A. Tajima, K. Tojo, R. Reynaud, M. Gueydan, A. Enjalbert, et al. Identification and Functional Analysis of the Novel S179R POU1F1 Mutation Associated with Combined Pituitary Hormone Deficiency J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4981 - 4987. [Abstract] [Full Text] [PDF]

				I. A. Demarco, T. C. Voss, C. F. Booker, and R. N. Day Dynamic Interactions between Pit-1 and C/EBP{alpha} in the Pituitary Cell Nucleus Mol. Cell. Biol., November 1, 2006; 26(21): 8087 - 8098. [Abstract] [Full Text] [PDF]

				R. Reynaud, M. Gueydan, A. Saveanu, S. Vallette-Kasic, A. Enjalbert, T. Brue, and A. Barlier Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3329 - 3336. [Abstract] [Full Text] [PDF]

				R. N. Cohen, T. Brue, K. Naik, C. A. Houlihan, F. E. Wondisford, and S. Radovick The Role of CBP/p300 Interactions and Pit-1 Dimerization in the Pathophysiological Mechanism of Combined Pituitary Hormone Deficiency J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 239 - 247. [Abstract] [Full Text] [PDF]

				R A Sporici, J S Hodskins, D M Locasto, L B Meszaros, A L Ferry, A M Weidner, C A Rinehart, J C Bailey, I M Mains, and S E Diamond Repression of the prolactin promoter: a functional consequence of the heterodimerization between Pit-1 and Pit-1 {beta} J. Mol. Endocrinol., October 1, 2005; 35(2): 317 - 331. [Abstract] [Full Text] [PDF]

				Y. Hashimoto, M. Cisternino, and L. E. Cohen A Novel Nonsense Mutation in the Pit-1 Gene: Evidence for a Gene Dosage Effect J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1241 - 1247. [Abstract] [Full Text] [PDF]

				L. E. Cohen and S. Radovick Molecular Basis of Combined Pituitary Hormone Deficiencies Endocr. Rev., August 1, 2002; 23(4): 431 - 442. [Abstract] [Full Text] [PDF]

				M.-H. Quentien, F. Pitoia, G. Gunz, M.-P. Guillet, A. Enjalbert, and I. Pellegrini Regulation of Prolactin, GH, and Pit-1 Gene Expression in Anterior Pituitary by Pitx2: An Approach Using Pitx2 Mutants Endocrinology, August 1, 2002; 143(8): 2839 - 2851. [Abstract] [Full Text] [PDF]

				S. Vallette-Kasic, A. Barlier, C. Teinturier, A. Diaz, M. Manavela, F. Berthezene, P. Bouchard, J. L. Chaussain, R. Brauner, I. Pellegrini-Bouiller, et al. PROP1 Gene Screening in Patients with Multiple Pituitary Hormone Deficiency Reveals Two Sites of Hypermutability and a High Incidence of Corticotroph Deficiency J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4529 - 4535. [Abstract] [Full Text] [PDF]